Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 14,300 Zymeworks Inc. $ZYME

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,300 shares of the company’s stock, valued at approximately $179,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZYME. EcoR1 Capital LLC grew its holdings in shares of Zymeworks by 14.8% in the first quarter. EcoR1 Capital LLC now owns 17,259,548 shares of the company’s stock valued at $205,561,000 after purchasing an additional 2,231,469 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Zymeworks by 184.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company’s stock valued at $46,210,000 after purchasing an additional 2,514,834 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Zymeworks by 0.4% in the 1st quarter. Deutsche Bank AG now owns 1,552,612 shares of the company’s stock worth $18,492,000 after buying an additional 5,840 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Zymeworks by 1.0% in the 1st quarter. Bridgeway Capital Management LLC now owns 766,944 shares of the company’s stock worth $9,134,000 after buying an additional 7,291 shares during the last quarter. Finally, Vestal Point Capital LP raised its position in shares of Zymeworks by 170.3% during the 1st quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $5,955,000 after buying an additional 315,000 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Zymeworks from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Leerink Partners set a $37.00 target price on Zymeworks in a report on Monday, November 17th. Citigroup raised their price target on Zymeworks from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, August 11th. B. Riley restated a “buy” rating and issued a $40.00 target price (up previously from $30.00) on shares of Zymeworks in a report on Friday, November 21st. Finally, HC Wainwright lifted their price target on shares of Zymeworks from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.13.

Zymeworks Stock Down 2.8%

Shares of Zymeworks stock opened at $26.57 on Friday. The stock’s fifty day moving average is $19.23 and its two-hundred day moving average is $15.40. Zymeworks Inc. has a 52 week low of $9.03 and a 52 week high of $28.49. The company has a market capitalization of $1.99 billion, a PE ratio of -17.71 and a beta of 1.48.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. The business had revenue of $27.61 million during the quarter, compared to the consensus estimate of $33.69 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The business’s revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period last year, the company earned ($0.39) earnings per share. As a group, research analysts anticipate that Zymeworks Inc. will post -1.39 earnings per share for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.